


Ceritinib-d₇

Cat. No.:	HY-15656S		
CAS No.:	1632484-77-5		
Molecular Formula:	C ₂₈ H ₂₉ D ₇ ClN ₅ O ₃ S		
Molecular Weight:	565.18		
Target:	Anaplastic lymphoma kinase (ALK); Insulin Receptor; IGF-1R; Isotope-Labeled Compounds		
Pathway:	Protein Tyrosine Kinase/RTK; Others		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description

Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

REFERENCES

[1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N₂-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. *J Med Chem.* 2013 Jul 25;56(14):5675-90.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA